Preferred Drug List (PDL): Reducing Costs through Comprehensive Therapy Management
Clinically-based. Smart. Efficient. Flexible. Comprehensive. These are just a few of the words that describe GHS’ Preferred Drug List (PDL) services, which include development, implementation, and maintenance. PDL is an area of excellence for GHS and one of the ways we reduce administrative costs, alleviate provider burden, and optimize net savings for our clients.
We design highly effective PDLs that position Medicaid programs to:
- Influence the prescribing habits of physicians;
- Implement a “Step Therapy” program;
- “Grandfather” drugs as not to interrupt current therapies;
- Improve patient outcomes; and
- Reduce the costs of pharmacy benefits (when combined with Supplemental Rebates).
We consider the clinical aspect of our PDL program a top priority, with highly qualified pharmacists leading the way. Our PDL experts review upwards of 200 new drugs weekly, focusing on safety, side effects, and drug interactions – balancing clinical and fiscal factors.
GHS realizes decisions are not always black and white. For example, the cost benefit of generics is not necessarily a given. Sometimes rebate programs make equally effective brand name drugs more financially attractive. We don’t make assumptions. We look for opportunities.